Search research articles
Contact Us
Filters
Showing results (531-540 of 580) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
Kerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Cancer Cell
|
December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Cell Reports
|
November 16, 2017
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Bradley Garman, Ioannis N Anastopoulos, Clemens Krepler, et al.
Nature Medicine
|
June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
Miguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Cancer Discovery
|
February 6, 2023
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Avinash Sahu, Xiaoman Wang, Phillip Munson, et al.
Nature Genetics
|
February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin, Amit J Sabnis, Elton Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Page
of 58
Search research articles
Search
Showing results (531-540 of 580) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma
Kerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
JCO Precision Oncology
|
August 17, 2022
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Matthew Dankner, Yifan Wang, Rouhi Fazelzad, et al.
JCO Precision Oncology
|
June 17, 2026
Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I
Shivaani Kummar, Zihe Song, Kim A Reiss, et al.
Cancer Cell
|
December 19, 2015
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
Kensuke Tateishi, Hiroaki Wakimoto, A John Iafrate, et al.
Cell Reports
|
November 16, 2017
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Bradley Garman, Ioannis N Anastopoulos, Clemens Krepler, et al.
Nature Medicine
|
June 2, 2015
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR
Miguel Vizoso, Humberto J Ferreira, Paula Lopez-Serra, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Cancer Discovery
|
February 6, 2023
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha
Avinash Sahu, Xiaoman Wang, Phillip Munson, et al.
Nature Genetics
|
February 10, 2015
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin, Amit J Sabnis, Elton Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 8, 2024
Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors
Ryan B Corcoran, Khanh T Do, Jeong E Kim, et al.
Page
of 58